Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Huntingtons Disease Treatment Market

Huntingtons Disease Treatment Market Share

Report ID: GMI10732
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Huntington’s Disease Treatment Market Share

The Huntington’s disease treatment industry is characterized by a dynamic competitive landscape, with significant market share held by key pharmaceutical companies that offer specialized therapies for symptom management. The collaborations between pharmaceutical firms, research institutions, and patient advocacy groups are driving advancements and expanding treatment options.

Huntington’s Disease Treatment Market Companies

Prominent players operating in the Huntington’s disease treatment industry include:

Bausch Health Companies Inc.
CHEPLAPHARM Arzneimittel GmbH
Dr. Reddy’s Laboratories Ltd.
H. Lundbeck A/S
Hikma Pharmaceuticals PLC
Lupin Limited
Neurocrine Biosciences, Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Upsher-Smith Laboratories, LLC.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Huntington’s disease treatment industry size was USD 457.5 million in 2023 and will grow at 20.8% CAGR between 2024 and 2032, driven by the increasing prevalence of the disease and growing awareness about neurodegenerative disorders.

The tetrabenazine segment held 47.8% share in 2023, primarily due to its proven efficacy in managing chorea, a primary symptom of the disease.

North America Huntington’s disease treatment industry achieved USD 183.9 million in 2023, propelled by its advanced healthcare infrastructure and significant investments in research and development.

Bausch Health Companies Inc., CHEPLAPHARM Arzneimittel GmbH, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Neurocrine Biosciences, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories, LLC., among others.